Sanofi ends Afrezza deal with MannKind

MannKind Corp. (NASDAQ:MNKD) sank $0.70 (48%) to $0.75 on Tuesday after Sanofi (Euronext:SAN; NYSE:SNY) terminated the companies' deal for Afrezza inhaled insulin. Sanofi spokesperson Susan Brooks said the decision

Read the full 296 word article

How to gain access

Continue reading with a
two-week free trial.